Merck & Co/MSD has agreed to buy privately held biotech Tilos Therapeutics for up to $773 million, its third pipeline-boosting deal in a little over four months. The deal gives Merck a pipeline of drugs for cancer, fibrotic and autoimmune dise...
Original Article: Merck bolts on another immunology firm with $773m Tilos deal